NM_001482.3:c.446G>A
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PVS1PP4_StrongPM2_SupportingPM3_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_001482.3:c.446G>A (p.Trp149Ter) variant in GATM is a nonsense variant predicted to cause a premature stop codon in biologically-relevant-exon 3/9 leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). Three siblings and a cousin with AGAT deficiency are all homozygous for the variant (PM3_Supporting). The proband in this family has total absence of the creatine/phosphocreatine peak on brain MRS, low urine GAA and creatine but normal blood levels; AGAT activity in lymphoblasts <0.3 nmol/hr/mg protein (normal 12.6–23.4)(PP4_Strong). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 7302). In summary, this variant meets the criteria to be classified as pathogenic for AGAT deficiency. GATM-specific ACMG/AMP codes met, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes VCEP (Specifications Version 1.1.0): PVS1, PP4_Strong, PM3_Supporting, PM2_Supporting.(Classification approved by the ClinGen CCDS VCEP on June 6, 2022). LINK:https://erepo.genome.network/evrepo/ui/classification/CA340668/MONDO:0012996/025
Frequency
Consequence
NM_001482.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- AGAT deficiencyInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Orphanet, Ambry Genetics, G2P
- Fanconi renotubular syndrome 1Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- primary Fanconi syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GATM | NM_001482.3 | c.446G>A | p.Trp149* | stop_gained | Exon 3 of 9 | ENST00000396659.8 | NP_001473.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461838Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 727216 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Arginine:glycine amidinotransferase deficiency Pathogenic:3Other:1
- -
- -
Variant confirmed as disease-causing by referring clinical team -
The NM_001482.3:c.446G>A (p.Trp149Ter) variant in GATM is a nonsense variant predicted to cause a premature stop codon in biologically-relevant-exon 3/9 leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). Three siblings and a cousin with AGAT deficiency are all homozygous for the variant (PM3_Supporting). The proband in this family has total absence of the creatine/phosphocreatine peak on brain MRS, low urine GAA and creatine but normal blood levels; AGAT activity in lymphoblasts <0.3 nmol/hr/mg protein (normal 12.6–23.4)(PP4_Strong). This variant is absent in gnomAD v2.1.1 (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 7302). In summary, this variant meets the criteria to be classified as pathogenic for AGAT deficiency. GATM-specific ACMG/AMP codes met, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes VCEP (Specifications Version 1.1.0): PVS1, PP4_Strong, PM3_Supporting, PM2_Supporting. (Classification approved by the ClinGen CCDS VCEP on June 6, 2022). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at